Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199899 | 0.82 | CA12 (0.48) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL4637449 | 0.81 | CA1 (0.42) | KDM4ELMNATSHRL3MBTL1ALDH1A1 | |
| SCHEMBL3778723 | 0.81 | LMNA (0.46) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL10167815 | 0.77 | CA12 (0.43) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL17557729 | 0.76 | CNR1 (0.33) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL1199921 | 0.76 | GLA (0.46) | CA12CA7CA14SMN1; SMN2LMNA | |
| SCHEMBL14452122 | 0.76 | CA12 (0.42) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL4806762 | 0.74 | CA12 (0.54) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL15693604 | 0.73 | CA12 (0.59) | KDM4ECA12CA7CA14SMN1; SMN2 | |
| SCHEMBL15693585 | 0.73 | CA12 (0.59) | KDM4ECA12CA7CA14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2009134666-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | KDM4E 4244/4885CA12 4158/4885CA7 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.